Prof. Sui Long (隋龙) — Cervical Precancer Precision Diagnosis & ASCCP Guidelines | Red House Hospital Shanghai
The accurate diagnosis of cervical precancerous lesions — determining which HPV-infected women have lesions that require treatment, which can be safely monitored, and which have been over- or under-diagnosed — is one of the most consequential clinical decisions in women's health. Get it wrong in one direction and women undergo unnecessary procedures with real risks to fertility and cervical function; get it wrong in the other and early cancers are missed. Prof. Sui Long (隋龙), Director of Cervicology at the Obstetrics & Gynecology Hospital of Fudan University (Red House Hospital), has dedicated his career to getting this right — and his contributions to the field have been recognized at the highest international level.
Prof. Sui is one of the very few Chinese clinicians to have contributed to the development of ASCCP guidelines — the guidelines of the American Society for Colposcopy and Cervical Pathology, which are the most widely referenced international standards for the management of cervical cancer screening results and precancerous lesions. He has also led the development of China's national cervical cancer screening guidelines and 20 clinical consensus documents — making him the single most influential figure in defining how cervical precancer is diagnosed and managed across China.
Specialty Focus
- Cervical precancerous lesions (CIN I–III): precision colposcopic diagnosis and management
- HPV infection: risk stratification, triage, and management
- Cervical cancer screening: protocol development and implementation
- Colposcopy: expert-level examination and biopsy
- LEEP and cold knife conization for CIN treatment
- Cervical cancer: early-stage diagnosis and surgical management
- Abnormal cervical screening results: second opinion and clarification
Academic & Clinical Titles
- Chief Physician & Professor, Director of Cervicology, Obstetrics & Gynecology Hospital of Fudan University (Red House Hospital)
- Contributor to ASCCP (American Society for Colposcopy and Cervical Pathology) guidelines
- Lead developer of China's national cervical cancer screening guidelines (《中国子宫颈癌筛查指南》)
- Lead developer of 20 clinical consensus documents in cervical disease management
ASCCP Guidelines: International Recognition of Chinese Expertise
The ASCCP — American Society for Colposcopy and Cervical Pathology — publishes the most widely used international guidelines for the management of abnormal cervical cancer screening results and cervical precancerous lesions. These guidelines are followed not only in the United States but by clinicians worldwide who seek evidence-based standards for managing HPV-positive results, abnormal Pap smears, and colposcopic findings.
Prof. Sui Long's contribution to ASCCP guideline development places him in an extraordinarily select group of Chinese clinicians whose expertise has been recognized and incorporated into international standards. This recognition reflects not only his clinical knowledge but his research contributions — the data and evidence that his work has generated have been deemed sufficiently robust to inform the guidelines that clinicians worldwide follow.
For international patients who have received abnormal cervical screening results and are uncertain about the appropriate next steps — particularly those who have received conflicting advice from different physicians — a consultation with Prof. Sui offers the unique assurance of an expert whose clinical judgment has been validated at the international guideline level.
Twenty Consensus Documents: Defining Chinese Cervical Cancer Practice
Beyond his international contributions, Prof. Sui has led the development of 20 clinical consensus documents governing cervical disease management in China — including China's national cervical cancer screening guidelines. These documents define the standards that gynecologists across China follow when managing HPV-positive patients, abnormal Pap smears, colposcopic findings, and CIN lesions.
The practical implication for patients is significant: when Prof. Sui evaluates a cervical screening result or colposcopic finding, he is not applying someone else's guidelines — he is the person who wrote them. His clinical judgment reflects the deepest possible familiarity with the evidence base underlying current recommendations, and his awareness of the limitations and uncertainties in that evidence base enables him to individualize management in ways that rigid guideline application cannot.
Precision Colposcopy: The Art and Science of Cervical Diagnosis
Colposcopy — the magnified examination of the cervix after application of acetic acid and Lugol's iodine — is the cornerstone of cervical precancer diagnosis. The quality of colposcopic examination varies enormously between practitioners: an expert colposcopist can identify subtle lesion characteristics that predict histological grade, guide biopsy to the highest-grade area, and distinguish true CIN from mimics — while a less experienced examiner may miss significant lesions or over-biopsy normal tissue.
Prof. Sui Long's colposcopic expertise, developed over a career dedicated to cervical disease, represents the highest level of this skill. His precision colposcopy approach integrates:
- Systematic lesion characterization: Assessment of acetowhitening intensity, margins, surface contour, vascular patterns, and iodine uptake to predict histological grade before biopsy
- Targeted biopsy: Directing biopsy to the highest-grade area within a lesion to minimize sampling error
- Endocervical assessment: Evaluation of the endocervical canal for lesions extending beyond the ectocervix, which require different management
- Correlation with screening results: Integration of HPV genotype, cytology grade, and colposcopic findings to determine the most appropriate management strategy
Who Should Consider Consulting Prof. Sui Long
- Women with abnormal cervical screening results (HPV-positive, abnormal Pap smear) who want expert guidance on next steps
- Women with CIN diagnoses who want a second opinion on whether treatment is necessary and what type is most appropriate
- Women who have had unsatisfactory colposcopy elsewhere and need expert re-examination
- Women with recurrent abnormal results after prior CIN treatment
- Women with discordant screening results (e.g., high-risk HPV positive but normal cytology, or abnormal cytology with negative colposcopy)
- Women seeking the most authoritative available interpretation of complex cervical screening results
- Healthcare providers seeking expert consultation on difficult cervical disease management cases
How CMCS Connects You with Prof. Sui Long
China Medical Concierge Shanghai (CMCS) facilitates access to Prof. Sui Long for international patients with HPV infection, abnormal cervical screening results, and cervical precancerous lesions. Our team manages the full coordination process — from remote case review and medical record translation to appointment scheduling, interpretation, and in-hospital support.
To begin, patients or their families are encouraged to share available medical records including HPV typing results (with specific genotypes if available), cervical cytology reports (Pap smear/ThinPrep/LBC), colposcopy reports and biopsy histology results, prior treatment history, and any relevant imaging. Prof. Sui's team can conduct an initial remote review of screening results before any travel to Shanghai is required.
CMCS provides end-to-end support including:
- Medical record translation (English, Arabic, French, and other languages)
- Remote pre-consultation screening result review
- Appointment coordination with Prof. Sui Long at Red House Hospital Shanghai
- On-site interpretation during colposcopy and consultations
- Post-consultation summary and follow-up support
Contact CMCS to Connect with Prof. Sui Long
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician.
0 commentaire